Cytosorbents Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cytosorbents Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.2 times its market value (net debt). Lower than 95% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 26% in 3 years; of every extra $100 of sales, $320 became extra profit. Higher than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-23.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 60% of Healthcare companies in United States.
Cash Locked Ratio
$27For every $100 of sales, $27 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $23 tied up three years earlier.
More money tied up than 58% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$320Sales grew 26% in 3 years; of every extra $100 of sales, $320 became extra profit.
Higher than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+26% / -30%In 3 years sales changed by +26% while total assets changed by -30%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-22.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 57% of Healthcare companies in United States.
Cash Cushion Ratio
1.2× debtDebt, after subtracting cash, is 1.2 times its market value (net debt).
Lower than 95% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 65% of Healthcare companies in United States.
Tangible Net Worth Ratio
45%Of every $100 of net worth, $45 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 55% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Cytosorbents Corporation made a loss over the last year. Cytosorbents Corporation owes $1.02 for every $1 it owns. Cytosorbents Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCytosorbents Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-25.22Cytosorbents Corporation's book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$19 MThe total market value of all of Cytosorbents Corporation's shares at today's price (share price × number of shares), smaller than 82% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeCytosorbents Corporation's net worth is negative ($1 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-336.2%Cytosorbents Corporation lost 336.2% of its shareholders' money over the last year, lower than 90% of Healthcare companies in United States.
Owes vs Owns
1.02×Cytosorbents Corporation owes $1.02 for every $1 it owns, so it owes more than it owns, higher than 87% of Healthcare companies in United States.
Dividend yield
NoneCytosorbents Corporation does not currently pay a dividend.
Revenue growth
+4%Revenue rose 4% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Profit growth
LossCytosorbents Corporation made a loss in each of the last two years.
Profit margin
-22.1%Cytosorbents Corporation lost $22 for every $100 of revenue.
Interest cover
Not coveredCytosorbents Corporation's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtCytosorbents Corporation had $23 M more debt than cash (net debt) at Dec 2025.
Questions
What is Cytosorbents Corporation's return on equity?
Cytosorbents Corporation lost 336.2% of its shareholders' money over the last year, lower than 90% of Healthcare companies in United States.
How much does Cytosorbents Corporation owe compared with what it owns?
Cytosorbents Corporation owes $1.02 for every $1 it owns, so it owes more than it owns, higher than 87% of Healthcare companies in United States.
Does Cytosorbents Corporation pay a dividend?
No. Cytosorbents Corporation does not currently pay a dividend.
Is Cytosorbents Corporation's revenue growing?
Revenue rose 4% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.